Rare and Recalcitrant Cancers for Establishing the Predictive Power of Patient-Derived Xenografts (PDXs)
$19,812,417N01FY2018CANIH
Leidos Biomedical Research, Inc., Frederick MD
Investigators
Abstract
Rare and Recalcitrant Cancers for Establishing the Predictive Power of Patient-Derived Xenografts (PDXs)
View original record on NIH RePORTER →